Pfizer Anticipates Slower Growth in 2026 Despite Efforts to Enhance Pipeline and Reduce Costs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 16 2025
0mins
Should l Buy BNTX?
Source: Benzinga
Fiscal 2026 Guidance: Pfizer projects adjusted earnings of $2.80-$3.00 per share and sales of $59.5 billion-$62.5 billion for 2026, both below consensus estimates, with anticipated revenue declines from COVID-19 products and loss of exclusivity for certain products.
2025 Performance and Guidance: The company affirmed its fiscal 2025 adjusted earnings guidance of $3.00-$3.15 per share and narrowed sales guidance to around $62 billion, aligning closely with market expectations.
R&D and Cost Management: Pfizer plans to allocate $10.5 to $11.5 billion for R&D in 2026, focusing on key therapeutic areas and ongoing clinical programs, while also managing operational expenses through a Cost Realignment Program.
BioNTech Stake Sale: Pfizer is reportedly selling its remaining stake in BioNTech, aiming for approximately $508 million from the sale of about 4.55 million American depositary receipts, with shares of both companies showing slight movements in premarket trading.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BNTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BNTX
Wall Street analysts forecast BNTX stock price to rise
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 110.230
Low
113.00
Averages
143.17
High
181.00
Current: 110.230
Low
113.00
Averages
143.17
High
181.00
About BNTX
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CDC Meeting to Address Vaccine Injuries and Long COVID
- Agenda Update: The CDC's upcoming meeting on March 18-19 will include discussions on COVID-19 vaccine injuries and long COVID, reflecting growing concerns over vaccine safety that could impact public trust in vaccinations.
- Meeting Postponement: The meeting, originally scheduled for February 25-27, was postponed due to a lawsuit from several medical groups, indicating strong opposition to the CDC's agenda that may affect vaccine policy formulation.
- Vaccine Injury Review: As Health and Human Services Secretary Robert F. Kennedy Jr. plans to revamp the National Vaccine Injury Compensation Program, the CDC's scrutiny of vaccine injuries could lead to increased regulation of vaccine developers like Pfizer, Moderna, and Novavax, impacting their market performance.
- Child Vaccine Committee Changes: Kennedy Jr. previously ended the terms of at least four members of the Advisory Commission on Childhood Vaccines, which may influence the committee's recommendations and subsequently affect the execution of the vaccine injury compensation program.
See More
BioNTech Sues Moderna Over Patent Issues
- Patent Lawsuit: BioNTech has filed a lawsuit against rival Moderna, alleging patent infringement related to COVID-19 vaccines, which could impact Moderna's market position.
- Intensified Market Competition: This lawsuit signifies an escalation in competition between the two companies in the COVID-19 vaccine sector, potentially leading to a reallocation of resources in R&D and marketing.
- Legal Risks: The lawsuit may trigger prolonged legal battles, affecting Moderna's financial performance and future product development plans.
- Industry Impact: This event could have a ripple effect across the biopharmaceutical industry, prompting other companies to reassess their patent strategies and competitive responses.
See More
Top Performing Large-Cap Stocks Last Week
- First Majestic Silver Surge: First Majestic Silver Corp. saw a 25.23% increase this week after reporting better-than-expected fourth-quarter adjusted EPS results, indicating strong profitability in the silver mining sector that may attract more investor interest.
- Omnicom Buyback Announcement: Omnicom Group Inc. rose 22.52% this week following better-than-expected Q4 sales results and the announcement of a $5 billion stock buyback plan, which is expected to enhance shareholder returns and boost market confidence.
- Garmin's Strong Financials: Garmin Ltd. jumped 18.66% this week after reporting fourth-quarter financial results that exceeded expectations and issuing FY26 guidance above estimates, suggesting ongoing growth potential in the smart device market.
- Pan American Silver's Recovery: Pan American Silver Corp. soared 15.54% this week after its fourth-quarter financial results surpassed expectations, reflecting robust performance in silver mining that could drive its future market performance.
See More
Walmart's Guidance Falls Short of Expectations
- Guidance Miss: Walmart's latest earnings report projects adjusted EPS for the fiscal year between $2.75 and $2.85, falling short of Wall Street's $2.96 forecast, resulting in a premarket stock drop of over 2%.
- Challenges Under New CEO: With John Furner taking the helm amid intensifying market competition, investor focus on his strategic direction is increasing, which could impact stock performance.
- Market Performance Review: Despite a recent stock increase of over 21% and nearly 175% over the past five years, the lowered guidance may raise concerns about Walmart's future growth potential among investors.
- Industry Dynamics Impact: On the same day as Walmart's report, Wayfair posted its first annual sales gain, while Etsy's stock rose after beating earnings expectations, indicating a potential pressure on Walmart from the recovering retail sector.
See More
BioNTech SE Stock Downgraded by Leerink Partners
- Rating Downgrade Impact: Leerink Partners downgraded BioNTech SE (NASDAQ:BNTX) from Outperform to Market Perform with a price target of $113, reflecting a 24% stock rally from December's low of $92, which outpaced the 4% gain of the biotechnology sector.
- Long-Term Outlook Positive: Despite the downgrade, Leerink Partners remains optimistic about BioNTech's long-term prospects, particularly regarding the development of pumitamig, a VEGFA/PD-L1 bispecific antibody partnered with Bristol Myers Squibb, indicating the company's potential in oncology.
- Strong Financial Position: BioNTech holds $20.3 billion in cash, expected to support the development of its oncology pipeline, ensuring robust financial backing for future research and development initiatives.
- Management Changes: On January 28, BioNTech appointed Kylie Jimenez as Chief People Officer, aiming to drive the company's strategy to become a multi-product oncology firm by 2030, with Jimenez responsible for shaping and executing the people strategy.
See More
Moderna's Flu Vaccine Receives FDA Review Approval
- FDA Review Decision: The FDA's agreement to review Moderna's experimental mRNA flu vaccine reverses its earlier refusal, stunning Wall Street and the medical community, marking a significant advancement in vaccine development.
- Positive Market Reaction: Following the FDA review announcement, Moderna's shares rose over 6%, reflecting investor confidence in the company's future flu vaccine market potential and paving the way for its goal of breaking even by 2028.
- New Application Strategy: Moderna's revised regulatory approach seeks full approval for adults aged 50 to 64 and accelerated approval for those 65 and older, addressing FDA criticisms of its trial design and enhancing the vaccine's market competitiveness.
- Changing Regulatory Environment: The FDA's decision highlights significant shifts in U.S. vaccine regulatory policies, particularly under the leadership of the new Secretary of Health and Human Services, with Moderna's application process facing stricter scrutiny, illustrating the complexities and challenges of vaccine regulation.
See More
CDC Meeting to Address Vaccine Injuries and Long COVID
- Agenda Update: The CDC's upcoming meeting on March 18-19 will include discussions on COVID-19 vaccine injuries and long COVID, reflecting growing concerns over vaccine safety that could impact public trust in vaccinations.
- Meeting Postponement: The meeting, originally scheduled for February 25-27, was postponed due to a lawsuit from several medical groups, indicating strong opposition to the CDC's agenda that may affect vaccine policy formulation.
- Vaccine Injury Review: As Health and Human Services Secretary Robert F. Kennedy Jr. plans to revamp the National Vaccine Injury Compensation Program, the CDC's scrutiny of vaccine injuries could lead to increased regulation of vaccine developers like Pfizer, Moderna, and Novavax, impacting their market performance.
- Child Vaccine Committee Changes: Kennedy Jr. previously ended the terms of at least four members of the Advisory Commission on Childhood Vaccines, which may influence the committee's recommendations and subsequently affect the execution of the vaccine injury compensation program.
See More
BioNTech Sues Moderna Over Patent Issues
- Patent Lawsuit: BioNTech has filed a lawsuit against rival Moderna, alleging patent infringement related to COVID-19 vaccines, which could impact Moderna's market position.
- Intensified Market Competition: This lawsuit signifies an escalation in competition between the two companies in the COVID-19 vaccine sector, potentially leading to a reallocation of resources in R&D and marketing.
- Legal Risks: The lawsuit may trigger prolonged legal battles, affecting Moderna's financial performance and future product development plans.
- Industry Impact: This event could have a ripple effect across the biopharmaceutical industry, prompting other companies to reassess their patent strategies and competitive responses.
See More
Top Performing Large-Cap Stocks Last Week
- First Majestic Silver Surge: First Majestic Silver Corp. saw a 25.23% increase this week after reporting better-than-expected fourth-quarter adjusted EPS results, indicating strong profitability in the silver mining sector that may attract more investor interest.
- Omnicom Buyback Announcement: Omnicom Group Inc. rose 22.52% this week following better-than-expected Q4 sales results and the announcement of a $5 billion stock buyback plan, which is expected to enhance shareholder returns and boost market confidence.
- Garmin's Strong Financials: Garmin Ltd. jumped 18.66% this week after reporting fourth-quarter financial results that exceeded expectations and issuing FY26 guidance above estimates, suggesting ongoing growth potential in the smart device market.
- Pan American Silver's Recovery: Pan American Silver Corp. soared 15.54% this week after its fourth-quarter financial results surpassed expectations, reflecting robust performance in silver mining that could drive its future market performance.
See More
Walmart's Guidance Falls Short of Expectations
- Guidance Miss: Walmart's latest earnings report projects adjusted EPS for the fiscal year between $2.75 and $2.85, falling short of Wall Street's $2.96 forecast, resulting in a premarket stock drop of over 2%.
- Challenges Under New CEO: With John Furner taking the helm amid intensifying market competition, investor focus on his strategic direction is increasing, which could impact stock performance.
- Market Performance Review: Despite a recent stock increase of over 21% and nearly 175% over the past five years, the lowered guidance may raise concerns about Walmart's future growth potential among investors.
- Industry Dynamics Impact: On the same day as Walmart's report, Wayfair posted its first annual sales gain, while Etsy's stock rose after beating earnings expectations, indicating a potential pressure on Walmart from the recovering retail sector.
See More
BioNTech SE Stock Downgraded by Leerink Partners
- Rating Downgrade Impact: Leerink Partners downgraded BioNTech SE (NASDAQ:BNTX) from Outperform to Market Perform with a price target of $113, reflecting a 24% stock rally from December's low of $92, which outpaced the 4% gain of the biotechnology sector.
- Long-Term Outlook Positive: Despite the downgrade, Leerink Partners remains optimistic about BioNTech's long-term prospects, particularly regarding the development of pumitamig, a VEGFA/PD-L1 bispecific antibody partnered with Bristol Myers Squibb, indicating the company's potential in oncology.
- Strong Financial Position: BioNTech holds $20.3 billion in cash, expected to support the development of its oncology pipeline, ensuring robust financial backing for future research and development initiatives.
- Management Changes: On January 28, BioNTech appointed Kylie Jimenez as Chief People Officer, aiming to drive the company's strategy to become a multi-product oncology firm by 2030, with Jimenez responsible for shaping and executing the people strategy.
See More
Moderna's Flu Vaccine Receives FDA Review Approval
- FDA Review Decision: The FDA's agreement to review Moderna's experimental mRNA flu vaccine reverses its earlier refusal, stunning Wall Street and the medical community, marking a significant advancement in vaccine development.
- Positive Market Reaction: Following the FDA review announcement, Moderna's shares rose over 6%, reflecting investor confidence in the company's future flu vaccine market potential and paving the way for its goal of breaking even by 2028.
- New Application Strategy: Moderna's revised regulatory approach seeks full approval for adults aged 50 to 64 and accelerated approval for those 65 and older, addressing FDA criticisms of its trial design and enhancing the vaccine's market competitiveness.
- Changing Regulatory Environment: The FDA's decision highlights significant shifts in U.S. vaccine regulatory policies, particularly under the leadership of the new Secretary of Health and Human Services, with Moderna's application process facing stricter scrutiny, illustrating the complexities and challenges of vaccine regulation.
See More
